<DOC>
	<DOCNO>NCT00791544</DOCNO>
	<brief_summary>The primary objective study select dose AVE1642 administer patient liver carcinoma eligible local treatment . The secondary objective study : - To evaluate safety profile AVE1642 single agent safety profile combination anti-cancer therapy interest liver carcinoma , include detection immunogenicity . - To evaluate pharmacokinetics pharmacodynamics profile AVE1642 single agent PK interaction give combination anti-cancer therapy . - To assess preliminary clinical activity term response rate ( Complete response + Partial response ) , duration response , stabilisation rate duration stabilisation , accord RECIST criterion . - To assess biological activity tumor level .</brief_summary>
	<brief_title>Dose Finding Study AVE1642 Patients With Advanced Metastatic Liver Carcinoma</brief_title>
	<detailed_description>AVE1642 administer IV infusion day 1 every 3 week least 2 infusion evaluability requirement . Curative / prophylactic management allergic reaction infusion implement need . The duration study one patient include period inclusion 2 week , least 2 cycle treatment dose escalation step ( one cycle AVE1642 alone least one cycle AVE1642 combination ) least one cycle combination extension cohort , follow , possible , minimum 30-day follow-up last drug administration , order detect potential immunogenicity . In second step , patient continue treatment disease progression , unacceptable toxicity willingness stop . The expected enrolment period 15 month least 30 day follow-up last patient treat .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients eligible surgical resection , liver transplantation , local ablation technique chemoembolisation histologically prove liver carcinoma whenever possible combination radiologically document hypervascular liver tumour α foeto protein level ≥ 400 ng/ml Signed date approved patient inform consent form prior enrollment study ECOG performance status &gt; 2 Inadequate organ function : Neutrophils ( ANC ) &lt; 1,500/mm3 Hemoglobin &lt; 10g/dl Platelets &lt; 100,000/mm3 Total bilirubin &gt; 1.5 x ULN ASAT , ALAT &gt; 3 x ULN Creatininemia &gt; 1.5 x ULN ( ≥ 2.0 mg/dl ) INR &gt; 1.6 Liver cirrhosis Child Pugh B C ( score &gt; 6 ) HbA1C &gt; 8 % No measurable evaluable tumoral lesion Patients eligible sorafenib therapy therapy postpone 3 week ( AVE1642 single treatment period ) dose escalation part Prior exposure antiIGF1R class compound The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>monoclonal antibody , anti IGF1R</keyword>
</DOC>